DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Yau T et al.
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Invest New Drugs 2012;
30: 2384-2390
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.